KR100966362B1 - Drug delivery system of inorganic plate powders-mesoporous silica composite and a method for preparing the same - Google Patents

Abstract

The present invention relates to a drug carrier of an inorganic plate-mesoporous silica composite and a method for preparing the same, wherein the secondary supported inorganic silica is supported after supporting a functional drug inside a mesoporous silica having nanoporous uniform pores. The present invention relates to a drug carrier in the form of a complex and a method for producing the same, which can exhibit stable and sustained drug loading and release performance by complexing to a powder.

Inorganic powder, talc, mesoporous, porous, silica, drug carrier, color cosmetics

Description

Drug delivery system of inorganic plate powders-mesoporous silica composite and a method for preparing the same}

The present invention relates to a drug carrier of the inorganic plate-mesoporous silica composite and a method for preparing the same, and more specifically, to a mesoporous silica having nano-level uniform pores, which exhibits excellent release control properties of cosmetic raw materials. A composite of an inorganic powder, and a drug delivery system using the same.

The cosmetics industry continues to grow every year, and production declined due to the slowdown in the domestic economy in 1998 and 2003. However, in the case of functional cosmetics, the output has increased from 310 billion to 400 billion. Recently, functional cosmetics are generally concentrated on basic products, but development is gradually progressing to color products. In Korea, functional cosmetics are approved, but it is not easy because the procedure is difficult, and the analysis of functions and effects must be performed through various clinical trials. Therefore, there is a demand for the development of a product formulation that is stable and maximizes the effect through the evaluation of the formulation and sustained release of the functional raw material.

Retinol, Vitamin C, and Arbutin, which are common functional ingredients of the functional base products currently produced, cause problems such as oxidation, discoloration, and discoloration through contact with water and air, In most cases they have properties that break the stability. In order to solve these problems, the company is developing various angles, and as a result, many efforts are being made to achieve stability and express functionality through methods such as product packaging and derivative synthesis.

TiO ₂ and ZnO, approved as functional inorganic powders, have been recognized for their ability to protect against UV rays, but they are known to reduce the use of cosmetics due to problems of high refractive index, relatively high specific gravity, and the structure of raw materials themselves. . However, TiO ₂ , which is superior to the sunscreen effect and is less likely to cause skin trouble as an inorganic powder, is used in large amounts as a cosmetic raw material despite its bad feeling of use. On the other hand, ZnO is generally known as a raw material for blocking UV A, but recently, the analysis is focused on the functionalities such as anti-aging of ZnO mainly in Japan.

Talc, mica, sericite and the like, which are used in large amounts as a raw material for color cosmetics, have been used in general color powder cosmetics due to the inherent properties of the powder having a plate shape, structural adhesion, and skin intimacy. In the case of color cosmetics, the water-repellent property of water becomes the basic specification of the product. Currently, most commonly used powders for cosmetic raw materials improve water repellency through the compounding of organic substances such as silicone oil, and sometimes the adhesion of powder and skin In order to improve intimacy, we use a combination of raw materials such as lecithin, ceramide, and plant phyto hormone.

In order to impart the functionality of color cosmetics, we are trying to develop a functional product by adding arbutin and vitamin C derivatives, which have stable properties to contact with moisture and air in the air, but discoloration, discoloration and structural change caused by long-term exposure. Due to problems such as the use of the functional raw materials with the problems such as the situation is difficult to develop by adding the functional raw material directly to the color tone products.

Development of cosmetic raw materials and formulations that can solve problems such as moisture stability in the air, airtightness, long-term stability, and feeling of use in cosmetics will be the most basic technology in developing functional color cosmetics. Accordingly, it is urgent to develop a carrier of a functional drug that is harmless to the human body.

At present, drug release research using silica is actively underway to overcome this problem. Bioceramic such as silica generally exhibits excellent bioactivity, and in the pharmaceutical system, it has excellent bone conductivity and can be used as a hard tissue substitute. In addition, it is known that the application field is very wide in drug delivery systems such as antibiotics, anticancer drugs, anti-inflammatory drugs, antiviral drugs, antibacterial agents, hormones for the treatment.

One of the ideal ways to deliver a functional drug accurately in the body is to deliver the drug directly to a specific site, such as the affected area. This method delivers the drug only to the parts of the body that need it, and the target may be aged cellular tissue on the skin, or it may be a cell unit outside the skin caused by melanin deposition by keratin. Therefore, if the drug is delivered only to the part requiring functionality, not only can the efficiency of the administered drug be improved, but also the drug can be prevented from being delivered to other sites, so that the effect can be seen at a desired amount in a small amount. There is an advantage that can meet the price part of the functional cosmetics.

In this regard, Korean Patent No. 588534 discloses a drug delivery system in which a drug is supported on a ceramic complexed with biodegradable porous silica, wherein silica silica gel or mesoporous silica is preferably adopted. According to the patent, the disclosed drug delivery system can be widely applied to antibiotics, anticancer agents, analgesics, anti-inflammatory agents and the like.

Meanwhile, drug delivery systems in functional cosmetics known in the art have existed only on organic materials. However, these organic materials are unstable at room temperature and have problems in their persistence, so a new method of functional cosmetics is needed. In this regard, it has been considered to fix such organic materials on inorganic materials, for example inorganic plate materials, and to use them as drug delivery systems. However, when the organic material is directly compounded on the inorganic material, an unstable chemical reaction causes a problem that the organic material flows without being fixed on the inorganic material. In particular, when using this type of structure as a hydrophilic drug delivery system, it can exhibit sufficient performance in terms of the amount of drug to be supported and controlled release of the intended drug, ie sustained release, with respect to the active ingredient, for example, glycoic acid. There was no.

Accordingly, the present inventors have continuously studied to improve the prior art, and after first loading the functional drug inside mesoporous silica having nano-level uniform pores, the secondary supported silica is compounded with an inorganic powder or powder. When stabilized, not only can effectively support drugs, especially hydrophilic drugs, but also have good controlled release properties of the drug, which is particularly desirable for drug delivery systems in functional cosmetics, where the continuous and stable properties are more emphasized. The present invention has been completed by confirming that it can be applied.

Accordingly, an object of the present invention is to present a stable and sustained drug loading and release performance by first loading a functional drug inside a mesoporous silica having nanoporous uniform pores and then complexing the secondary supported silica with an inorganic powder. It is to provide a drug carrier in the form of a complex.

Another object of the present invention is to provide a drug delivery system using the drug delivery system.

It is another object of the present invention to provide a method for preparing the drug carrier.

In order to achieve the above object, according to the first aspect of the present invention, a hydrophilic head of mesoporous silica carrying a drug in a hydrophilic head domain generated on the surface of a plate-like inorganic powder The parts are combined to be combined to provide a drug carrier having a supporting function.

According to a second aspect of the invention,

a) chelating the inorganic plate powder with a divalent metal;

b) coating an organic material on the inorganic plate-like powder chelated with the divalent metal;

c) supporting the drug in mesoporous silica; And

d) it provides a method for producing a drug carrier comprising the step of complexing the mesoporous silica carrying the drug on the inorganic plate-like powder coated with the organic material.

According to a third aspect of the present invention, there is provided a drug delivery system (DDS) using the drug delivery system.

In the present invention, "mesoporous" refers to the arrangement of pores, channels and arbitrary cages, and the arrangement of pores, channels and cages may be regular or periodic. The pores or channels can be separated or interconnected and can be one, two or three dimensional. In addition, the pore size is nanoscale, meaning that it has a size of 2 to 50 nm (20 to 500 kHz), preferably 3 to 10 nm (30 to 100 kHz).

In the present invention, "mesoporous silica" means having a very uniform pore size and arrangement in the structure, in particular, at the nano level in diameter, from 2 to 50 nm (20 to 500 kHz), preferably from 3 to 10 nm (30). To 100 microns) of regular, uniformly sized porous silica.

In the present invention, "drug carrier" means a drug carrier that includes not only sustained release of the drug for a long time but also the concept of predictability and regeneration. Thus, in the present invention the drug is released at a predetermined rate over a predetermined time at a reproducible rate. Such controlled drug carriers have the advantage of maintaining the blood concentration of the drug in the treatment area for a long time by controlling the release rate of the drug when the bioavailability is low or the absorbency of the drug is so large that it is lost out of the body too quickly. . Mechanisms for controlling drug release of such agents include diffusion, dissolution, osmotic pressure or ion exchange, and most of these methods are used in combination.

Hereinafter, the present invention can be achieved by the following description with reference to the accompanying drawings. The following description describes preferred embodiments of the present invention, but the present invention is not necessarily limited thereto.

1 schematically illustrates a series of processes for preparing a drug carrier of a complex by secondary complexing a mesoporous silica carrying a functional drug on an inorganic platelet powder complexed with an organic substance such as lecithin according to a preferred embodiment of the present invention. It is shown.

The lipid, i.e. lecithin, which is an organic substance, generally has a flowability that is difficult to fix on the inorganic substance, but by chelating the surface of the inorganic substance with a divalent metal, these lipid vesicles are flowable on the inorganic substance. It can be effectively combined. At this time, the plate-like characteristic is lost in the region where the organic material (lipid) is combined. This process can be more clearly understood from the following examples.

Then, mesoporous silica carrying a functional drug is bonded to a hydrophilic head domain of the lipid vesicle through a sol-gel reaction using a silica precursor. That is, the mesoporous silica that is additionally complexed serves to fix the organic material that is unstablely located on the inorganic material. In this manner, the hydrophilic head portion in the double layer of the lipid vesicle is silicated to form the plate-like structure again.

In the present invention, the "inorganic substance" is a plate-shaped inorganic material, preferably plate-shaped inorganic powder, produced naturally or synthetically as plate metal hydroxide, plate silicate, plate aluminosilicate and plate metal oxide. It is understood as a concept that includes all, preferably talc, sericite or mica.

The talc is represented by the chemical formula Mg ₃ (OH) ₂ Si ₄ O ₁₀ , contained in crystalline schist rock, produced in a large mass in a basic plutonic rock such as serpentine rock, and is produced by the alteration of minerals containing magnesium. In addition, a high quality product containing almost no iron as an impurity in talc becomes a material for processing art paper, and is also used in cosmetics, horse riding, thermal insulation, and fireproof materials.

On the other hand, the biotite, sericite, is a plate-shaped inorganic material having a cryptocrystalline form of muscovite, represented by the formula KAl ₂ (OH) ₂ (AlSi ₃ O ₁₀ ).

In the present invention, the inorganic material used for preparing the carrier, preferably the plate-shaped inorganic material, has a specific surface area of about 60 to 90 m ² / g and a particle size in the range of about 440 to 470 nm, in terms of the physical properties preferred. This range of properties is to be understood in an illustrative sense, and the scope of the present invention is not limited thereto.

According to the present invention, chelating agents of divalent metals are used for surface modification of inorganic materials. Mg, Ca, and Ba can be exemplified as such a divalent metal, and preferably Mg is used. As such, the Mg compound is preferable as a chelating agent because Mg is an essential mineral component in vertebrates, except for K, it is the most abundant ion in the human body. In particular, it is known to require the kinase (kinase), phosphatase Mg ^{2 +} ions in order to activate a number of enzymes containing a phosphate compound such as (phosphatase). Moreover, Mg ions are involved in physiological and biochemical processes such as RNA, DNA or protein synthesis, and membrane stabilization.

In the present invention, the divalent metal chelate compound may include anhydrous chloride, sulfate, acetate, and the like. In particular, in the case of Mg compound, magnesium acetate tetrahydrate, 98 %, ACS reagent) is preferable.

In the present invention, lecithin may be used as the preferred organic substance, that is, the lipid component. The lecithin is a constituent of the cell membrane and generally contains a phosphatide fraction derived from egg yolk or soybean. Phosphatidylcholine (PC), the main component of lecithin, is represented by the following formula (1).

In the present invention, the silica precursor can be selected and used without particular limitation as long as it can mainly synthesize silica as an alkoxide compound. The silica precursor may be selected from tetraethylorthosilicate (TEOS), tetramethylorthosilicate (TMOS), and combinations thereof, and preferably tetraethylorthosilicate is used.

According to a preferred embodiment of the present invention, the method for preparing a drug carrier of the inorganic plate-porous silica composite may include four steps as follows. The following production method is not limited to the present invention as an illustrative purpose.

The first step is a) chelating the inorganic platelet powder with a divalent metal, wherein a solution obtained by dissolving a chelating divalent metal compound in water or alcohol, preferably ethanol, and mixing the plate-shaped inorganic powder with stirring As a result, the divalent metal ions are adsorbed on the surface of the inorganic powder to form a bridge. In this case, the mixing time may be appropriately adjusted in consideration of reaction conditions of the lecithin complexing step, which is a subsequent step, and is not particularly limited. However, typically about 4 to 8 hours is appropriate. In this regard, as the concentration of the divalent metal compound in the solution increases, more -OH groups are formed on the surface of the inorganic powder, and in consideration of the coupling effect of -OH groups, preferably about 0.5 to 1.5 M, More preferably, it is adjusted to a concentration range of about 0.8 to 1.2 M, most preferably about 1.0 M level.

The second step is b) complexing the organics on the inorganic platelet chelated with the divalent metal, contacting the inorganic powder chelated with the divalent metal by dissolving lecithin in water or alcohol, preferably ethanol. This is the step. At this time, the stirring may be performed for easy contact, and a high pressure homogenizer may be preferably used as the equipment for the stirring. In addition, the lipid vesicle solution may be contacted with the inorganic powder at least twice so that a sufficient amount of lecithin is contained between the plates of the inorganic powder. After this step, the lipid vesicle is preferably in the form of droplets having a size ranging from about 1527 to 1926 nm.

The third step is to c) support the drug in mesoporous silica, to prepare a mesoporous silica having a nano-sized uniform size pores, and then impregnated the drug into the drug to support the drug inside the silica. . Here, mesoporous silica used as porous silica is hydrogen-bonded tetraethylorthosilicate to the hydrophilic portion of the surfactant P123, and then the organic-inorganic hybrid silica material reacted is grafting method or It is prepared by introducing reactive or inert organic groups in the plate powder using a co-condensation method. Imparting organic functions to silica materials can control surface polarity (hydrophilicity, hydrophobicity, binding to guest molecules), change surface reactivity, protect surfaces from external attack, change material bulk properties (mechanical and scientific), etc. It can be done.

Finally, the fourth step is d) complexing the porous silica carrying the drug on the inorganic plate powder complexed with the organic material, and complexing the porous silica carrying the functional drug on the lipid complexed inorganic powder. . In this case, the porous silica may be silicaized through a sol-gel process known in the art.

Silica, like amorphous silica, has many silanol (Si-OH) groups on its surface, which serves as a point to fix organic functionality. The surface change to the organic group is made through a silylation reaction, although the silanol group is likely to cause an esterification reaction with ethanol or the like. In general, silylation is through one of three reaction schemes described in Scheme 1 below.

The maintenance of silanol groups is the most important consideration, and for this purpose, the bonding is carried out under sufficient agitation, followed by minimizing cleaning to maintain the silanol groups, and calcining at 500 to 600 ° C. to remove the surfactant P123, preferably Calcined to 550 ° C.

According to the present invention, the complex can be usefully applied as a drug carrier in a drug delivery system. In particular, the silicated region having pores on the organic material of the composite has the advantage of not only effectively supporting the drug, but also providing easy release control properties.

In a preferred embodiment of the present invention, the supportable drug may be, but is not limited to, a hydrophilic drug. Specifically, glycoic acid (glycolic acid) that can exert effects such as whitening, wrinkle improvement, exfoliation and the like as a material of high functional cosmetics is mentioned.

In the present invention, a technique for supporting a drug using the complex as a carrier is well known in the art, and the present invention is not limited to a specific supporting method.

The present invention stabilizes an unstable functional drug by complexing mesoporous silica carrying a drug in an inorganic plate-like powder complexed with an organic substance such as lecithin, thereby effectively restraining the instability in question in the process of carrying a functional material. Excellent emission control properties. In particular, since the supporting and sustained release properties of hydrophilic drugs such as glycoic acid are excellent, a wide range of applications to high-functional cosmetics is expected in the future.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to Examples and Experimental Examples. These examples are only for illustrating the present invention, but the scope of the present invention is not limited by these examples.

Example  1-1: Mg - Chelated Talc Powder  Produce

Anhydrides of magnesium chloride (MgCl; FW: 95.22, Sigma) were added to deionized water to prepare solutions of 0.1M, 0.25M, 0.5M, 0.75M, and 1M, respectively. ₁₀ g of talc (chemical formula: Mg ₃ (OH) ₂ Si ₄ O ₁₀ ) powder having a particle size of 226.2 nm was added to each of the solutions, followed by stirring at room temperature for 5 hours. Then, filtered through ethanol and dried completely at room temperature. As a result, Mg-chelated talc powder was obtained.

As described above, FT-IR analysis was performed on each powder obtained by varying the concentration of Mg compound in the solution. The apparatus used for the analysis was a JASCO V-460 FT / IR spectrometer (Wavelength Range: 650-4000 nm; using Miracle Single reflectance ATR; Resolution: 4 cm ^-1 ; Scan times: 30 times). The results are shown in FIG.

2, it can be seen that as the concentration of the Mg compound increases -OH group on the surface of the talc increased. Therefore, the experiments were subsequently conducted using a powder obtained from a 1 M magnesium chloride solution, where the most -OH is produced.

Example  1-2: Mg - Chelated Serisite  Preparation of Powder

₁₀ g of sericite (formula: KAl ₂ (OH) ₂ (AlSi ₃ O ₁₀ )) powder having a particle size of 250.2 nm was added to a 1 M magnesium chloride solution, and the mixture was stirred at room temperature for 5 hours. Then, filtered through ethanol and dried completely at room temperature. As a result, Mg-chelated sericite powder was obtained.

Example  2-1: Lecithin Coated Mg - Chelated Talc  Powder manufacturing

A lecithin-coated Mg-chelated talc powder was prepared by coating lecithin on the Mg-chelated talc powder obtained from the 1 M magnesium chloride solution.

That is, 2g of lecithin (from egg, TCI) was dissolved in deionized water (98g), and stirred at room temperature for 3 hours or more. The lecithin vesicle solution at room temperature was prepared in a vesicle solution prepared through the homogenizer under atmospheric pressure condition (1 atm), and dried in a vacuum to prepare a white powder form. 10 g of the Mg-chelated talc powder obtained from the 1M magnesium chloride solution was added to 10 g of the lecithin vesicle solution, followed by stirring at room temperature for 24 hours, followed by filtration with a filter paper, followed by room temperature and air atmosphere conditions. Dried under.

 As a result, it was possible to prepare a sample (Twin cake) that is the actual cosmetics and a sample that matches the lipid component more than 80%. As a result, the manufacturing method of the twin cake is generally different for each cosmetic company, but it was confirmed that the mixing with silica is easy when the talc and the lecithin are used as described above.

Example  2-2: Lecithin Coated Mg - Chelated Serisite  Powder manufacturing

The lecithin was coated on the Mg-chelated sericite powder in the same manner as in Example 2-1, except that Mg-chelated sericite powder obtained from 1 M magnesium chloride solution was used.

Example  3: Mesoporous  Silica manufacturing

Mesoporous silica was prepared as follows.

First, 4 g of surfactant P123, 120 g of 2M HCl, and 120 g of H ₂ O were stirred for 8 hours while maintaining at 40 ° C. Tetraethylolsosilicate (TEOS) was 8.5 g dorpwise to the stirred solution, followed by stirring for 8 hours at 40 ° C. After overnight aging at 120 ° C., the aged solution was filtered and dried at room temperature and calcined at 550 ° C. As a result, mesoporous silica with homogeneous pores was produced.

Example  4: the drug is Impregnated Mesoporous  Silica manufacturing

A mesoporous silica impregnated with a drug substance was prepared by impregnating a mesoporous silica prepared above with a functional material, that is, a drug. The drug used was glycoic acid (99%, FW: 76.05; Sigma).

Specifically, a mesoporous silica impregnated with glycoic acid was prepared by taking 3 g of mesoporous silica and immersing in 0.05M glycoic acid / ethanol solution for 24 hours and drying at room temperature for 3 days.

Example  5: Plaque Inorganic powder (TC)  The drug Impregnated Mesoporous  Preparation of Composites of Silica

10 mL of EtOH (purity 99%) was added to 10 g of the powder prepared in Example 2.1, stirred at room temperature for about 1 hour, and then slowly mixed with 10 g of mesoporous silica impregnated with the drug prepared in Example 4, Stir at least 5 hours.

Experimental Example  One: FE - SEM  And TEM  analysis

FE for Examples 1 and 2, (a) talc powder, (b) lecithin-coated talc powder, (c) sericite powder, (d) lecithin-coated sericite powder -SEM analysis was performed.

The results are shown in Fig. 3, it can be seen that the edge of the inorganic powder before compounding is sharp while the edge has a smooth curved surface after compounding, and the surface layer of the inorganic powder on the plate before compounding and the surface layer after compounding. There was a lot of difference. That is, according to FIG. 3, the state of the composite starch has a sharp edge as the shape of the plate itself, and each plate is separated (FIG. 3 (a) and (c)), but The surface is also ambiguous in the separation of the plate, it can be seen that the sharp interface between the plate and the plate disappears, especially due to the flow of organic matter (Fig. 3 (b) and (d)).

In Example 3, (a) TEM analysis on the appearance of pores of mesoporous silica, and (B) FE-SEM analysis on mesoporous silica were performed.

The results are shown in FIG. TEM analysis showed that the pore of mesoporous silica was uniformly well formed.

Experimental Example  2: FT - IR  analysis

In Examples 1 to 5, the base lecithin-coated Mg-chelated talc powder, that is, Twin cake (TC), a complex of mesoporous silica in the TC, 2.91% by weight glycoic acid as a drug in the TC, 6.54 wt%, 9.03 wt%, and 13.1 wt% of the composite of mesoporous silica impregnated respectively, FT-IR analysis was performed on mesoporous silica alone, and the apparatus used was used in Example 1-1. Same as the device. The results are shown in FIG.

As a result, peaks were found at 3700, 3000-2800, 1700, 1500-1250, and 1000. Since TC itself is a cosmetic powder containing organic matter, it can be seen that organic matter peaks are found at 3000 ~ 2800. In addition, a peak appearing in inorganic powder characteristics such as talc was found around 3700. Mesoporous had no characteristic peak, but it was found that the Si peak appeared around 1000. Glycolic acid is an organic material, so a peak occurs at 3000 ~ 2800. This peak is the same as the peak from TC itself and does not exhibit any characteristic. In addition, in FIG. 5, a peak is formed at 1500 to 1250, which is determined as a peak of a metal that binds the powder and the organic material as a peak of the divalent metal.

Experimental Example  3: drug release test

Tests on the supporting properties of the drug were performed to evaluate the applicability of the lecithin-coated Mg-chelated talc powder-drug loaded mesoporous silica complex as a carrier of the drug delivery system. In addition, the supporting properties were evaluated in the same manner with respect to mesoporous silica alone before silicaization.

Each 3 g of mesoporous silica was taken and soaked in 0.05 M glycoic acid / ethanol solution for 24 hours and then dried at room temperature for 3 days. 0.5g of dried mesoporous silica material was taken and used in a functional raw material, that is, a drug release experiment, wherein the glycoic acid content was 2.91% by weight, 6.54% by weight, 9.03% by weight, and 13.1% by weight, respectively. A standard concentration calibration curve of the functional raw material was obtained by diluting the functional raw material of 0.05M in order to express the absorbance of the functional raw material by using an ultraviolet-visible spectrophotometer. The concentration of the functional raw material was measured by extrapolation using the obtained standard concentration calibration curve. The functional raw material was released at room temperature and 40 ℃ for 2 hours. The collected samples were measured for absorbance and then evaluated for their supporting properties in terms of concentration.

PBS (Phosphate Buffer Calculator, Monobasic monohydrate: 1.1832g, Dibasic ACS reagent: 8.1572g) 0.01M as a solvent for the release test was prepared, pH was adjusted to 7.4. After drawing a standard curve with each drug, the test was performed by preparing for each molar concentration. The calibration curve for each drug was obtained by measuring absorbance. The apparatus used was a JASCO V-550 UV-Vis Spectrometer (Wavelength Range: 200-900 nm; Bandwidth Selectable: 0.5 nm; Scanning Speed: 400 nm / min; Data Pitch: 1 nm). First, the absorbance was measured, and then a quantitative curve was obtained, and the emission concentration was tested using this.

As a result, the emission profile according to the concentration of glycoic acid as shown in FIG. 6 was obtained.

6, it was shown that according to the degree of support of glycoic acid, the amount of glycoic acid supported therein was more released. In addition, the mesoporous silica used in the present invention, which has a large number of uniform pores at the nano level and has a large surface area, has a larger capacity than the silica having irregular pores in terms of its ability to support drugs. It was expected to be able to support the drugs and to release these drugs over a long time. In the graph of the upper right of the graph of Figure 6 it can be seen that the emission graph showing the sum of the amount of the emission to represent a step shape. This is a phenomenon that occurs when the drug is released from silica, and it shows that the drug is not released when it moves through the channel. This indicates that the release is possible selectively and facilitates the release for a long time.

Experimental Example  4: present invention Inorganic Plate Powder - Mesoporous  Evaluation of Skin Application of Silica Composites

Twin cake prototypes were prepared using the mesoporous silica composite carrying the present invention lecithin-coated Mg-chelated talc powder-drug prepared through the above examples to evaluate the quality. The drug was evaluated as a product containing 13.1% glycoic acid, and as a control was used a product that does not apply the drug-supported mesoporous silica.

The prepared product is shown in Figure 7, the skin application evaluation results are shown in Table 1 below.

Evaluation item Control Invention Twin Cake Moist × ○ Application × ○ Softness × ○ Brightness after skin application × ○ [State] ○: Good, ×: Bad

As can be seen from Table 1, the TC (twin cake) containing the mesoporous silica impregnated with the functional drug of the present invention was found to be better than the normal TC, such as moistness, spreadability, softness, brightness after skin application.

As described above through the above Examples and Experimental Examples, the present invention primarily carries a functional drug in mesoporous silica having a uniform pore at a nano level, and then composites the secondary supported silica into an inorganic powder, that is, a powder. And stabilization, which not only can effectively support drugs, especially hydrophilic drugs, but also have excellent controlled release properties of the drug, which can provide a drug delivery system in functional cosmetics in which these properties are persistent and stable. Since it has an effect, it is a very useful invention in the cosmetic industry.

1 schematically illustrates a series of processes for preparing a drug carrier of a complex by secondary complexing a mesoporous silica carrying a functional drug on an inorganic platelet powder complexed with an organic substance such as lecithin according to a preferred embodiment of the present invention. It is shown.

Figure 2 shows the results of the FT-IR analysis for each Mg-chelated talc powder obtained by varying the concentration of the Mg compound in the chelating agent solution.

Figure 3 shows the results of FE-SEM analysis for (a) talc powder, (b) lecithin-coated talc powder, (c) sericite powder, (d) lecithin-coated sericite powder. It is shown.

Figure 4 shows the results of TEM analysis of the appearance of pores of (a) mesoporous silica, (b) FE-SEM analysis of mesoporous silica.

5 is a base lecithin-coated Mg-chelated talc powder, that is, Twin cake (TC), a composite of mesoporous silica in the TC, 2.91% by weight of glycoic acid, 6.54% by weight of the drug to the TC, The composites of mesoporous silica impregnated with 9.03% by weight and 13.1% by weight, respectively, show the results of FT-IR analysis on mesoporous silica alone.

6 shows the release profile according to the concentration of glycoic acid on the carrier.

Figure 7 is a photograph showing the appearance of a general twin cake and a twin cake to which the present invention mesoporous silica is applied. Wherein A is a control and B is a twin cake of the invention.

Claims (11)

delete delete delete delete delete a) chelating the inorganic plate powder with a divalent metal; b) coating an organic material on the inorganic plate-like powder chelated with the divalent metal; c) supporting the drug in mesoporous silica; And d) a method for preparing a drug carrier comprising mixing a mesoporous silica carrying a drug on the inorganic plate-like powder coated with the organic material. 7. The method of claim 6, wherein the inorganic plate-like powder is talc, sericite or mica. 7. The method of claim 6, wherein the divalent metal is Mg, Ca, or Ba. 7. The method of claim 6, wherein the organic material is lecithin. 7. The method of claim 6, wherein the mesoporous silica has a pore size of 2 to 50nm. 7. The method of claim 6, wherein the drug is glycoic acid.

Images